Stay updated with breaking news from Fairmount Funds. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pro-forma cash, cash equivalents and marketable securities expected to fund the Company into 2027 and through clinical readouts from ongoing SUMMIT, PEAK and APEX registration-directed trials
– Stephen Mahoney appointed President and Chief Executive Officer – – Potential best-in-class subcutaneous and intravenous thyroid eye disease programs targeting insulin-like growth factor 1...
Inflammation and immunology biotech Apogee Therapeutics and Sagimet Biosciences, a company developing a drug for the fatty liver disease NASH, are the latest biotech companies to join the public markets. Both companies upsized their IPOs, raising cash for clinical trials.
Apogee Therapeutics has filed to raise $100 million in a U.S. IPO, although the final figure may differ. Read more about APGE IPO here.